- Home
- GLSI vs RDCM Comparison
GLSI vs RDCM Comparison
Compare GLSI & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- RDCM
- Stock Information
- Founded
- GLSI 2006
- RDCM 1985
- Country
- GLSI United States
- RDCM Israel
- Employees
- GLSI N/A
- RDCM N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- GLSI Health Care
- RDCM Technology
- Exchange
- GLSI Nasdaq
- RDCM Nasdaq
- Market Cap
- GLSI 197.1M
- RDCM 157.9M
- IPO Year
- GLSI 2020
- RDCM 1997
- Fundamental
- Price
- GLSI $12.56
- RDCM $12.02
- Analyst Decision
- GLSI Strong Buy
- RDCM Strong Buy
- Analyst Count
- GLSI 1
- RDCM 1
- Target Price
- GLSI $38.00
- RDCM $14.00
- AVG Volume (30 Days)
- GLSI 29.1K
- RDCM 65.6K
- Earning Date
- GLSI 11-14-2024
- RDCM 01-29-2025
- Dividend Yield
- GLSI N/A
- RDCM N/A
- EPS Growth
- GLSI N/A
- RDCM 660.55
- EPS
- GLSI N/A
- RDCM 0.46
- Revenue
- GLSI N/A
- RDCM $58,755,000.00
- Revenue This Year
- GLSI N/A
- RDCM $18.92
- Revenue Next Year
- GLSI N/A
- RDCM $11.27
- P/E Ratio
- GLSI N/A
- RDCM $25.43
- Revenue Growth
- GLSI N/A
- RDCM 17.80
- 52 Week Low
- GLSI $8.00
- RDCM $7.70
- 52 Week High
- GLSI $21.44
- RDCM $12.84
- Technical
- Relative Strength Index (RSI)
- GLSI 43.69
- RDCM 55.45
- Support Level
- GLSI $12.90
- RDCM $11.50
- Resistance Level
- GLSI $13.73
- RDCM $12.80
- Average True Range (ATR)
- GLSI 0.70
- RDCM 0.52
- MACD
- GLSI -0.09
- RDCM -0.06
- Stochastic Oscillator
- GLSI 4.28
- RDCM 47.35
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.